Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BioMed X, Boehringer Ingelheim join forces
February 2020
SHARING OPTIONS:

HEIDELBERG, Germany—BioMed X and Boehringer Ingelheim have kicked off a new joint research group at the BioMed X Innovation Center in Heidelberg that will investigate myelination deficits in the adolescent brain and their connection to the development of schizophrenia. As the human body matures, the brain is reorganized in a variety of ways, including cortical myelination, dendritic arborization, synaptic pruning and circuit plasticity. Evidence has shown that genetic, epigenetic and environmental factors can adversely affect this process and increase risk for schizophrenia. This new effort will look specifically into myelination deficits, developing in-vitro and in-vivo platforms to assess oligodendrocyte development and myelination, with a goal of identifying novel neuronal and oligodendrocytic factors that impact myelination as possible targets for preventing the development of schizophrenia.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.